ClinicalTrials.gg

Hypertriglyceridemia clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 324 studies for Hypertriglyceridemia across more than 10 countries. 38 are recruiting or about to start. 198 of them are mainly about Hypertriglyceridemia (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17.

Status

Completed
220
Recruiting
22
Status unknown
20
Terminated
18
Active, not recruiting
16
Not yet recruiting
15

Phase

Phase 2
81
Phase 3
62
Phase 1
38
Phase 4
37
Early Phase 1
4

Where

United States
150
Canada
51
China
26
France
18
Germany
17
Hungary
17

Who develops what

Add Hypertriglyceridemia to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 13 programs from 12 companies, 12 with this as their studies’ main aim; 2 with a live phase 3 study; 5 primary completions in the next 12 months. Compare Jiangsu HengRui Medicine, Arrowhead Pharmaceuticals and CSPC Pharmaceutical Group here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
eicosapentaenoic acid ethyl esterRecent, limited
Evidence
  • NCT07680829 · Huadong Medicine Co., Ltd. · Phase 3 · live · background · “Icosapent Ethyl Oral Capsule” · registered Jun 2026
  • NCT04177680 · Matinas BioPharma Nanotechnologies, Inc. · Phase 2 · comparator · “icosapent ethyl” · registered Nov 2019
Amarin Pharma Inc.50% of its industry studiesUS: off-patent, 11 generics marketedEU: RECORDATI GROUP (EMA 2021)11 study
FenofibrateEarlier only
Evidence
  • NCT03011450 · Kowa Company, Ltd. · Phase 3 · background · “Fenofibrate” · registered Dec 2016
  • NCT03001817 · Kowa Company, Ltd. · Phase 3 · background · “Fenofibrate” · registered Nov 2016
  • NCT02354976 · AstraZeneca · Phase 2 · comparator · “Fenofibrate 200mg” · registered Jan 2015
  • NCT01594983 · Novartis · Phase 2 · background · “Fenofibrate” · registered May 2012
  • NCT01539616 · Zydus Lifesciences Limited · Phase 2 · comparator · “Fenofibrate” · registered Feb 2012
Abbott42% of its industry studiesUS: off-patent, 35 generics marketed00 studies
AtorvastatinEarlier only
Evidence
  • NCT04882293 · laboratorios silanes s a de c v · Phase 3 · comparator · “Atorvastatin (Lipitor ®)” · registered Apr 2021
  • NCT00973271 · Neurocrine Biosciences · Phase 3 · background · “atorvastatin” · registered Sep 2009
  • NCT00435045 · GlaxoSmithKline · Phase 3 · comparator · “atorvastatin” · registered Feb 2007
Viatris Inc.16% of its industry studiesUS: off-patent, 23 generics marketed00 studies

3 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
plozasiranApproved: US 2025 · EU 2026☆ Track2 live phase-3 studies: NCT06822790, NCT06880770Arrowhead Pharmaceuticals
DR10624☆ Track2 live phase-3 studies: NCT07693777, NCT07680829Huadong Medicine Co., Ltd.

The 2 in phase 3 with the nearest primary completion, of 13 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (5)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Mar 2027 est.solbinsiran · Eli Lilly and Company · Phase 2 main aimNCT07269210 A Study of Solbinsiran (LY3561774) in Participants With Severe Hypertriglyceridemia — primary endpoint: Change from Baseline in Triglycerides · 60 enrolled
  • Mar 2027 est.RBD5044 · Ribotek Biopharmaceuticals (Shandong) Co., Ltd · Phase 2 main aimNCT07587788 RBD5044 in Chinese Participants With Hypertriglyceridemia — primary endpoint: Change from baseline in fasting serum triglyceride (TG) levels at week 16 · 40 enrolled
  • Jun 2027 est.HRS-7249, SHR-1918 · Jiangsu HengRui Medicine Co., Ltd. · Phase 2 main aimNCT07308392 Phase II Clinical Trial Evaluating the Efficacy and Safety of HRS-7249 and SHR-1918 in Patients With Severe Hypertriglyceridemia at High Risk of Acute Pancreatitis — primary endpoint: Percentage change in mean TG from baseline at weeks 44 and 48 of treatment · 119 enrolled

2 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Hypertriglyceridemia studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Statins 7

Coming up

21studies finish main data collection within a year3 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 22 Hypertriglyceridemia studies recruiting now, 9 (41%) set no upper age limit and 12 (55%) stop at 75 or younger. 2 (9%) take children under 18. 2 (9%) are for women only and 0 (0%) for men only; 4 (18%) take healthy volunteers.

Recruiting studies that take each age, of 22
AgeWomenMen
102 (9%)1 (5%)
1820 (91%)19 (86%)
3022 (100%)20 (91%)
4022 (100%)20 (91%)
5021 (95%)20 (91%)
6520 (91%)19 (86%)
7515 (68%)14 (64%)
8510 (45%)9 (41%)

Across all 324 studies, recruiting or not: 56% stop at 75 or younger and 26% at 65; 11% take children; 2% are for women only and 2% for men only; 26% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Hypertriglyceridemia studies take

Of 29 phase 3 interventional studies under Hypertriglyceridemia, half reached primary completion within 24 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 120 mo16–28 · 15 studies——
Phase 221 mo10–40 · 23 studies——
Phase 324 mo18–31 · 29 studies24 mo18–31 · 28 studies—
Interventional, no phase23 mo7–39 · 45 studies—23 mo7–39 · 42 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 324. Browse all 324 → or search them.